SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007887
Filing Date
2022-05-05
Accepted
2022-05-05 16:39:47
Documents
79
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q srne-20220331.htm   iXBRL 10-Q 2400360
2 EX-10.1 srne-ex10_1.htm EX-10.1 120833
3 EX-10.2 srne-ex10_2.htm EX-10.2 4473
4 EX-31.1 srne-ex31_1.htm EX-31.1 16262
5 EX-32.1 srne-ex32_1.htm EX-32.1 10701
  Complete submission text file 0000950170-22-007887.txt   9740094

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT srne-20220331_def.xml EX-101.DEF 263672
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT srne-20220331_lab.xml EX-101.LAB 513545
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT srne-20220331_pre.xml EX-101.PRE 410024
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT srne-20220331_cal.xml EX-101.CAL 70412
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT srne-20220331.xsd EX-101.SCH 60184
73 EXTRACTED XBRL INSTANCE DOCUMENT srne-20220331_htm.xml XML 1826612
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36150 | Film No.: 22897078
SIC: 2836 Biological Products, (No Diagnostic Substances)